Even though Amgen Inc. continues to see sales of multiple blockbuster products decline due to biosimilar and generic competition, the company reported better than expected third quarter 2019 revenue of $5.74bn, down 3% year-over-year, but above analyst consensus of $5.62bn. However, sales of newer drugs needed to make up for declining sales of older products fell short of expectations.
Amgen’s sales of Aimovig (erenumab) for migraine prevention totaled $66m, down from $83m in the second quarter, the company revealed...








